Previous close | 1.1000 |
Open | 1.1000 |
Bid | 1.0600 x 100 |
Ask | 1.1300 x 100 |
Day's range | 1.0800 - 1.1100 |
52-week range | 0.8400 - 2.0300 |
Volume | |
Avg. volume | 129,022 |
Market cap | 41.178M |
Beta (5Y monthly) | 0.99 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.8300 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 4.54 |
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
– BDC-1001 (trastuzumab imbotolimod) Phase 2 studies in four HER2-positive tumor types advancing toward 2024 milestones– BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balance of $128.6 million as of December 31, 2023, anticipated to fund key milestones through late 2025 REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapi
REDWOOD CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will present a company overview at the TD Cowen 44th Annual Healthcare Conference on Tuesday, Mar. 5, at 2:50 p.m. EDT (11:50 a.m. PDT) in Boston, Massachusetts. A live webcast of the presentation will be available on the Events and Presentations page of Bolt’s website